Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy

Case report: Plasma cell leukemia secondary to multiple myeloma successfully treated with anti-BCMA CAR-T cell therapy

Chimeric antigen receptor (CAR)-T cell therapy provides an effective salvage treatment for relapsed/refractory multiple myeloma (RRMM) patients. End-stage RRMM with plasma cell leukemia (PCL) transformation is highly aggressive and resistant to conventional therapy. There is an urgent need for new t...

Full description

Bibliographic Details
Main Authors: Jingjing Deng, Yuehui Lin, Defeng Zhao, Chunrong Tong, Alex H. Chang, Wenming Chen, Wen Gao
Format: Article
Language:English
Published: Frontiers Media S.A. 2022-09-01
Series:Frontiers in Oncology
Subjects:
plasma cell leukemia
relapsed/refractory multiple myeloma
chimeric antigen receptor T cell therapy
secondary plasma cell leukemia
treatment
Online Access:https://www.frontiersin.org/articles/10.3389/fonc.2022.901266/full

Internet

https://www.frontiersin.org/articles/10.3389/fonc.2022.901266/full

Similar Items